FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to a new pharmaceutical composition for the treatment of psoriasis containing Sivelestat (5% wt) as an active component which selectively suppresses psoriasis-specific inflammatory mediators at the local level.
EFFECT: disclosed is a pharamaceutical composition that selectively suppresses inflammatory mediators specific for psoriasis at the local level, which helps to avoid the disadvantages characteristic of drugs based on glucocorticoids.
4 cl, 1 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF FORMING A LABORATORY MODEL OF PSORIASIS IN IMIQUIMOD-INDUCED INFLAMMATION IN EXPERIMENTAL ANIMALS | 2020 |
|
RU2736000C1 |
| 2-ARYL-SUBSTITUTED N-ARYLIMIDAZOLINES, SELECTIVE CYCLOOXYGENASE-2 INHIBITORS, METHODS FOR PRODUCTION AND USE THEREOF | 2014 |
|
RU2565667C1 |
| METHOD FOR EVALUATING THE ANTIPSORIATIC EFFECT OF AN EXTERNAL AGENT ON A LABORATORY MODEL OF IMIQUIMOD-INDUCED PSORIASIS | 2021 |
|
RU2764549C1 |
| ANTI-INFLAMMATORY AND ANTI-ALLERGIC MEDICATION AND BASED ON IT PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2426540C1 |
| AMIDE DERIVATIVES OF POLYCAFFEOYLQUINIC ACIDS, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2742769C2 |
| PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2589699C2 |
| THERAPEUTIC AGENT CONTAINING COMBINATION OF ACTIVE SUBSTANCES CONTAINING PANTOTHENIC ACID OR ITS DERIVATIVES FOR TREATING ALLERGIC SYMPTOMS | 2008 |
|
RU2472499C2 |
| THERAPEUTIC COMPOSITION FOR TREATING DERMATOPATHIES (VERSIONS) | 2010 |
|
RU2456976C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PLAQUE PSORIASIS WITH OTHER CHRONIC SKIN DISEASES | 2019 |
|
RU2703314C1 |
| ANTIPSORIATIC COSMETIC COMPOSITION IN A GEL FORM | 2020 |
|
RU2742411C1 |
